Mutational screening was performed by sequencing two polymerase chain reaction-amplified CHRNA2 DNA fragments, spanning the whole exon 6 and exon 7, respectively, which code for 75 % of the mature protein and contain all four transmembrane domains contributing to the ion pore.
No mutations were identified in the analyzed region of CHRNA2.
These data demonstrate the rarity of the identified CHRNA2 mutations in NFLE patients, supporting the recently reported hypothesis of a restricted role for this gene in the disease.